Temsirolimus

From Wikipedia, the free encyclopedia

Temsirolimus
Systematic (IUPAC) name
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S, 23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24, 25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy- 3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]- 1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexameth 3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28, 29(4H,6H,31H)-pentone 4′-[2,2-bis(hydroxymethyl)propionate]
Identifiers
CAS number 162635-04-3
ATC code  ?
PubChem 6918289
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Licence data

EUUS

Pregnancy cat.

?

Legal status

POM(UK) -only(US)

Routes Intravenous

Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007,[1] and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.

The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months).[2] The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated.

[edit] References